Öz

Amaç: Omalizumab kullanan hastalarda COVİD-19 pandemisinin etkisini araştıran az sayıda çalışma bulunmaktadır. Bu çalışmada, omalizumab tedavisi alan hastalarımızda COVİD-19 pandemisinin etkilerinin araştırılması amaçlandı.

Gereç ve Yöntemler: Çalışmaya iki merkezden toplam 20 hasta katıldı. Hastalara tarafımızca hazırlanan 45 sorudan oluşan anket ve görsel analog skala (0: minimum, 10: maksimum) yüz yüze uygulandı.

Bulgular: Altı hastanın (%30) pandemi döneminde omalizumab tedavisine devam etmediği görüldü. Hastaların %90’ı (n=18) maske takıyorken, %85’i (n=17) sosyal mesafeye dikkat ettiğini belirtti. Çalışmamızda omalizumab kullanan hastalarda COVİD-19 enfeksiyon sıklığı %10 (n=2)’di. Pandemi ile hastalarımızın ders çalışma alışkanlıkları olumsuz etkilenirken (n=10, %50), iştahlarının arttığı (n=8, %40) ve uyku düzeninde değişiklikler (n=8, %40) olduğu tespit edildi.

Sonuç: COVİD-19 pandemisi hastalarımızın tedavi ve takiplerini önemli ölçüde etkilemiştir. Sonuçlarımız, omalizumab kullanımının COVİD-19 enfeksiyonu riskini artırmadığı görüşünü desteklemektedir.

Anahtar Kelimeler: Astım, COVİD-19, Ürtiker, omalizumab

Referanslar

  1. Del Rio C, Malani PN. COVID-19—new insights on a rapidly changing epidemic. JAMA 2020;323:1339-40.
  2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from:https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid-19—11-march-2020. Accessed March 15, 2020.
  3. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5.
  4. Stokes J, Casale BT, Anti-IgE therapy, Available at: www.UpToDateInc.com/card, Accessed Apr 24, 2020.
  5. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005;11:27-34.
  6. Denman S, Ford K, Toolan J, Mistry A, Corps C, Wood P, et al. Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol 2016;175:1405-7.
  7. Novartis receives European Commission approval for self-administration of Xolair across all indications. Available from: https://www.novartis.com/news/ media-releases/novartis-receives-european-commission-approval-self-administr ation-xolair-across-all-indications. Accessed March 15, 2020.
  8. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, et al. Severe Asthma and Biological Therapy: When, Which, and for Whom. Pulm Ther 2020;6:47-66.
  9. Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1043-57.
  10. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson M, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 2016;38:2058–2070.
  11. Leru PM, Anton VF. Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic. Cureus 2021;17;13:e17268.
  12. Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention 2019. Available from: https://ginasthma.org. Accessed March 15, 2020.
  13. Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, et al. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis. J Allergy Clin Immunol Pract 2020;8:2360-2369.e1.
  14. Tarbox JA, Gutta RC, Radojicic C, Lang DM. Utility of routine laboratory testing in the management of chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2011;107:239-43.
  15. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007;40:216-25.
  16. Liu S, Zhi Y, Ying S. COVID-19, and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol 2020;59:78-88.
  17. The American Academy of Allergy, Asthma & Immunology (AAAAI). Available from: https://www.aaaai.org/ask-the-expert/covid. Accessed March 31, 2020.
  18. American College of Allergy, Asthma and Immunology. Available from: https://acaai.org/news/important-information-about-covid-19- those-asthma. Accessed March 31, 2020.
  19. British Thoracic Society. Available from:https://www.brit-thoracic.org.uk/about-us/covid-19- information-for-the-respiratory-community/. Accessed March 31, 2020.
  20. Centers for Disease Control and Prevention (CDC). COVID-19: People who are at higher risk - people with asthma. Available from: https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/asthma.html. Accessed January 05, 2020.
  21. Self-administration of Xolair prefilled syringe (PFS) for asthma during the COVID-19 pandemic. Available from: https://www.gene.com/ medical-professionals/medicines/Xolair. Accessed April 23, 2020.
  22. King C, Cox F, Sloan A, McCrea P, Edgar JD, Conlon N. Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective. World Allergy Organ J 2021;14:100587.
  23. Timmermann H, Mailänder C. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians. Pneumologie 2020;74:103-11.
  24. Klimek L, Pfaar O, Worm M, Eiwegger T, Hagemann J, Ollert M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband
  25. Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische
  26. Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select 2020;7;4:53-68.
  27. Deolmi M, Pisani F. Psychological and psychiatric impact of COVID-19 pandemic among children and adolescents. Acta Biomed 2020;10;91:e2020149.
  28. Ding X, Yao J. Peer Education Intervention on Adolescents’ Anxiety, Depression, and Sleep Disorder during the COVID-19 Pandemic. Psychiatr Danub 2020;32:527-35.
  29. Shanahan L, Copeland WE, Angold A, Bondy CL, Costello EJ. Sleep problems predict and are predicted by generalized anxiety/depression and oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2014; 53:550-8.
  30. López-Moreno M, López MTI, Miguel M, Garcés-Rimón M. Physical and Psychological Effects Related to Food Habits and Lifestyle Changes Derived from Covid-19 Home Confinement in the Spanish Population. Nutrients 2020;12:3445.
  31. Cekic S, Karali Z, Cicek F, Canitez Y, Sapan N. The Impact of the COVID-19 Pandemic in Adolescents with Asthma. J Korean Med Sci 2021;36:e339.
  32. Radu MC, Schnakovszky C, Herghelegiu E, Ciubotariu VA, Cristea I. The Impact of the COVID-19 Pandemic on the Quality of Educational Process: A Student Survey. Int J Environ Res Public Health 2020;17:7770.
  33. Gopal R, Singh V, Aggarwal A. Impact of online classes on the satisfaction and performance of students during the pandemic period of COVID 19. Educ Inf Technol (Dordr) 2021;26:6923-47.

Telif hakkı ve lisans

Nasıl atıf yapılır

1.
Karalı Z, Çekiç Ş, Özdemir Ö, Canıtez Y, Sapan N. Pandemi Döneminde Omalizumab Tedavisi Alan Hastaların Değerlendirilmesi. Turk J Pediatr Dis [Internet]. 2023 Mar. 22 [cited 2025 May 25];17(2):118-25. Available from: https://turkjpediatrdis.org/article/view/988